Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7932240 Phosphadiazine HCV polymerase inhibitors IV

Patent 7932240 was granted and assigned to Idenix Pharmaceuticals on April, 2011 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Idenix Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Jean-Laurent Paparin0

Claire Pierra0

Cyril Dousson0

Dominique Surleraux0

Arlène Roland0

Date of Patent

April 26, 2011

Patent Application Number

12198895

Date Filed

August 27, 2008

Patent Citations Received

US Patent 12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

0

US Patent 11690860 Treatment of HCV infected patients with cirrhosis

0

US Patent 11707480 Highly active compounds against COVID-19

0

US Patent 11975016 2′-substituted-N

0

US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

0

Patent Primary Examiner

Rei Tsang Shiao

Patent abstract

Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV′, I″, II″, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7932240 Phosphadiazine HCV polymerase inhibitors IV

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.